{"classes":[{"categories":[{"measurements":[{"comment":"The median duration of response based on Kaplan-Meier estimate had not been reached by the 15 July 2014 data cut-off date.","groupId":"OG000","lowerLimit":"10.550","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"Duration of response was calculated for the responders as the time from the initial documented response (CR or VGPR or PR) to the first documented progression or death due to any cause, whichever occurred first. Duration of response for participants last known to be alive with no progression after a CR, VGPR, or PR were censored at the date of last adequate response assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Lenalidomide 25 mg orally once daily for 21 days in each 28-day cycle until progressive disease or lenalidomide discontinuation for any reason.\n\nDexamethasone 40 mg orally once daily on Days 1, 8, 15 and 22 in each 28-day cycle until progressive disease or lenalidomide discontinuation for any reason.","id":"OG000","title":"Lenalidomide Plus Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"Efficacy Evaluable (EE) Population consists of all participants who meet protocol requirements (all eligibility criteria) and were evaluated after receiving at least one dose of study drug","reportingStatus":"POSTED","timeFrame":"From the first dose of study drug treatment until the data cut-off date of 15 July2014. Median follow up time was 61.6 weeks.","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}